Member Info for PhilBanks

Chester - I think you have summarised the situation very nicely there. Especially the point regarding institutional appetite for pursuing further hprc trials (and associated cost). Now the dust has settled somewhat, it will be interesting to hear them outline their strategy at the investor meeting on the 4th Feb.

Soon = early 2022

Might be difficult to believe based on what's happened recently here, but codiak is actually down more in the last 12 months than Rene (-78% vs -70%).

Not sure if that's a good thing or a bad thing, but it does at least provide some context of how badly small cap biotech has been hammered in the past year, regardless of the individual circumstances.

Sorry, where has this 10 million order been plucked from? I get that stockpiling will occur, but why would they want 10 million doses, and how could SNG realistically produce that amount within a reasonable time frame?

Don't get me wrong, I would be happy to see such an order (and ones from other countries), just not sure how you have arrived at such a figure.

hRPC is being suspended and out licenced specifically to avoid any more capital raise. It's an expensive programme, and the outcome sadly holds less promise than it once did. Ross is a savvy character, and no doubt if he wasn't involved the company would probably have spent another couple of years looking at further phase 2a studies, along with a significant fund raise and a full scale obliteration of shareholder value with no certain outcome.

However, on a brighter note, the chances of them securing an exosomes deal haven't changed since the hRPC RNS of last week. If/when they can secure such an outcome, then the landscape would change fundamentally overnight, and from the current share price level it could bring some very significant upside.

I still haven't been able to bring myself to buy any more since the RNS (thankfully), however it is now so cheap that it's almost being valued on a cash basis. You would presume that it has to bounce at some point, but sentiment is so shattered right now that nobody appears to be willing to catch the knife.

I think it's recognition that it's the exosomes that are responsible for how the treatment actually works. That doesn't mean that injecting the CTX cells isn't a valid way to treat the patients, instead it suggests that if they were starting again now then they would be designing the study in a different way.

CTX is at phase 2b and it has taken over a decade to reach that point. There's no reason why it can't be a commercial product in itself, if the data proves the efficacy of the treatment.

Really useful, thanks for sharing. Much more info than the prelims presentation.

Don't fully know, but I'm presuming the latest RNS relates to how services and expertise are provided by Rene to Fosun, to allow labs and analytics to be set up to the standards required for the cells to be cultured and preserved.

Whereas the April 2019 sets out the terms for how the product will be licenced, milestone payments and royalties. Part of the original deal seems to require Rene to provide all the cells etc, whereas now Fosun seem keen to be able to produce them in house, which Olav implies is good news as it demonstrates a commitment to the programme.

That's my reading anyway. You could email the company and ask for clarification (and post on here if you get a response), as it's not all totally clear to me.

Figures mentioned hardly set the heart racing at this stage, but it does at least demonstrate that the fosun deal is active and that we can presumably expect further movement here over the coming months.

*psychiatrist

Pretty sure they do want to sign a deal, in fact I would say that is their top priority now.

As a side note, I can't help but think the title of this thread sounds like an episode of Fraiser. Hopefully we're not all in need of a physiatrist for keeping the faith here. . . .

I don't know enough about him to offer any meaningful insight, but the fact that he's involved in a tug of war between two leading exosomes companies suggests that he must certainly be well respected. The fact that he's returning to rene also suggests that he too must be enthused by the POC data they have recently produced. Bodes well.

Hi surprised. They have POC data in hand, which according to the CSO represents the most exciting breakthrough in the 15 years he's been involved in the exosomes field (refer to the preliminary results presentation).

This data is therefore presumably equivalent to, or better than, the kind of pre-clinical POC data that codiak and evox secured their billion dollar collaboration deals on in recent years.

On this basis, assuming the findings can be replicated with one of the ongoing major pharma collaborations, then it seems to me that we could be looking at negotiating a similar kind of deal as and when those data emerge.

Would concur. But now, for me, exosomes deal seems an inevitability. Timescales are uncertain; given that the POC data produced so far is with an academic institution, then we may be reliant on them producing equivalent data with one of their major pharma collaborations, with a deal to then be negotiated off the back of that.

All said, I'm personally very comfortable with where we stand. Picked up two more tranches at 75p and 82p recently, so hopefully some good value moving forwards.

Reneuron consistently stands out amongst its peers as being the one that's worth peanuts.

Its either fundamentally undervalued, or the technology is fundamentally flawed and destined to fail. We'll find out the answer this year without a shadow of doubt (... pretty sure I said that at the start of last year as well, but hey ho).

I'm not in any way anti-vax, but from my own experience I had the pfizer vaccine and after the first dose had heart palpitations and fluttering etc for around a week afterwards. Foolishly waited a month before actually going to the doctors after I read an article about that vaccine. They did tests and said everything looked fine. I asked if I should go ahead with 2nd vaccine despite what happened with first dose and the doctor said 'we always recommend you have your second dose'. I'm 36 and just don't think the risk reward profile is in my favour for having the second dose, doctor seemed to just ignore that and gave me the stock answer.

I mentioned in the telegram group yesterday that the Retina UK video description states the following:

'ReNeuron:
Still at phase 2, but there are a very small number of UK participants – just two or three at Oxford – and the BBC have filmed a news piece. Results of phase two by middle of 2022, then will decide whether to move forward to phase 3.'

So they've already done the filming. The first patient was treated at Oxford 18th October.
https://tools.euroland.com/tools/Pressreleases/GetPressRelease/?ID=3976417&lang=en-GB&companycode=uk-rene&v=

BBC wouldn't be doing a piece about a treatment that doesn't work; presumably waiting for Reneuron to release preliminary data in Q1 2022 before the news piece goes on TV. Are we back to being excited about hRPC again??

Very good find, thanks for sharing.

Yes, sorry meant 1:100. Think OH and MH picked some up around 200p in February or March 2019, and both again in the 70p raise this time last year. Not huge amounts though obviously, but as stated, they both have significant options, as does the new CFO.

I think it's not just linked to the level of progression of the disease, but also the gene defect that has caused the RP. Cones and rods affect different aspects of the vision. I think (but admittedly don't know enough about it), that gene defects that cause the cones to die off more rapidly, are the ones that are most associated with decreased central visual field at an earlier stage. I think rods are more to do with light sensitivity.

If the above is true, the jcyte subset may well be restricted more by gene defects that are linked to cone degeneration. The same of course could ultimately be true for Reneuron's treatment, but the dataset isn't big enough yet to draw any conclusions. This may also be why we had some really fantastic responses in certain patients at 1m cells, and then some not so great responses in other patients. The key is to getting more and more patients through the trials as data is king. Very disappointing how long it's taking to get people enrolled currently.